Edesa Biotech, Inc. · NASDAQ:EDSA

Edesa Biotech — Investor Presentation (January 2024)

46 slides from Edesa Biotech's investor presentation, January 2024

  1. Slide 1: Corporate Presentation

    f 3B Wey | Edesa Biotech Corporate Presentation

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "

  3. Slide 3: Edesa Highlights

    Edesa Highlights Advancing First-in-Class Therapeutics for Immuno-Inflammatory Diseases First-in-Class Targets Toll-like Receptor 4 (TLR4) C-X-C motif chemokine ligand 10 (CXCL10) Secretory phospholipase A2 (sPLA2) Clinical Stage Pipeline and Data EB05: Ph2 data in critically ill ARDS suggest potent

  4. Slide 4: First-in-Class Development Pipeline

    First-in-Class Development Pipeline Advancing First-in-Class Therapeutics for Immuno-Inflammatory Conditions Indication Asset Program Pre-Clinical Phase 1 Phase 2 Phase 3 Status Comments/Milestones (Organ System) Anti-TLR4 EB05 Ph3 funding from the Canadian ARDS - Covid-19 Lead Asset Enrolling (Mono

  5. Slide 5: Large Addressable Market Opportunities

    Large Addressable Market Opportunities Across Chronic and Acute, High-Cost Critical Care Total Addressable Markets* Few FDA approved therapies and $6.0B significant share of voice $15B Annually $5.0B $5.2B $4.7B Attractive health economics proposition $4.0B $3.9B Accessible with focused commercial $

  6. Slide 6: Milestone-Rich Clinical Calendar

    Milestone-Rich Clinical Calendar 12 to 24 months Next 6 months EB01 (daniluromer) Partnering for Phase 3 2022 - 2023 EB05 (paridiprubart) & regulatory meetings Ph 2 IND for SSc-ILD 2021 EB05 (paridiprubart) and IPF EB05 (paridiprubart) C$23m govt. funding Enrollment and data1 Vitiligo 2020 SIF Grant

  7. Slide 7: Paridiprubart

    Paridiprubart First-in-Class Anti-TLR4 mAb

  8. Slide 8: The Role of Toll-like Receptor 4 (TLR4)

    The Role of Toll-like Receptor 4 (TLR4) TLR4 is a Key Upstream Mediator of Inflammatory and Fibrotic Processes Cellular Injury Infections Viral Viral Traumatic DAMPs PAMPs Bacterial Immune-mediated Toll-like Receptor 4 TLR4 (not activated) TLR4 (activated) Nobel Prize in 2011 for its discovery Activ

  9. Slide 9: TLR4 plays a Crucial Role in Inflammation and Fibrosis

    TLR4 plays a Crucial Role in Inflammation and Fibrosis Important Mediator of a Cascade of Processes that Culminate in ARDS and Lung Fibrosis 1 Cellular Injury Proinflammatory and profibrotic DAMPs 3 Cellular Injury results in Viral Progressive inflammation can Traumatic culminate on dysregulated pro

  10. Slide 10: Paridiprubart – Anti-Toll-like Receptor 4 (TLR4) Antibody

    Paridiprubart – Anti-Toll-like Receptor 4 (TLR4) Antibody First-in-Class mAb that Specifically Blocks TLR4 Signalling 1 Paridiprubart Interferes with TLR4 dimerization in a ligand independent manner Drug Profile NFκB AP-1 IRF3 A humanized IgG1k monoclonal antibody Binds to TLR4 with high affinity IL

  11. Slide 11: EB05: Paridiprubart for ARDS

    EBO5 Paridiprubart for ARDS 3 Edesa Biotech

  12. Slide 12: Acute Respiratory Distress Syndrome (ARDS)

    Acute Respiratory Distress Syndrome (ARDS) A Leading Cause of ICU Admissions Globally A life-threatening form of respiratory failure • Exaggerated immune response • Inflammation and injury to the lungs • Edema that deprives the body of oxygen Multiple triggers v • Infections by virus or bacteria as

  13. Slide 13: ARDS Treatment Paradigm

    ARDS Treatment Paradigm Current Options Available Rely Primarily on Supportive Care and a Small Number of Drugs DIAGNOSIS The Berlin definition is the gold standard Based on chest imaging and oxygenation levels Oxygenation is used to classify patients as mild, moderate or severe 40% TREATMENT Mortal

  14. Slide 14: A Significant Burden and Market Opportunity

    A Significant Burden and Market Opportunity Total Addressable Market Disease Burden 600,000 7 to 21 days $100K+ Estimated ARDS-Related of ICU stay for surviving average cost per patient ICU Admissions/Year $5.2B ARDS patients1 in the US2 v v ARDS across the 7 major markets (US, UK, Germany, France,

  15. Slide 15: EB05 – Phase 2 Clinical Efficacy

    EB05 – Phase 2 Clinical Efficacy Signal-Finding Component; Wide Population and Variety of Endpoints Efficacy of EB05 in Subjects Phase 2 population Hospitalized with Covid-19 Infection 315 Hospitalized Covid-19 patients WHO Severity scale from level 4 to level 7 EB05 (15mg/kg) + SOC Phase 2 Identify

  16. Slide 16: Phase 2 Clinical Efficacy Demonstrated

    Phase 2 Clinical Efficacy Demonstrated Statistically Significant Mortality Trend in Critical Patients Profound Efficacy Signal for Mortality Reduction Phase 2 – Preemptively unblinded by independent data (28-Day Mortality Rate; n=33, p=0.04) safety monitoring board (DSMB) • Strong efficacy signal fo

  17. Slide 17: U.S./Canada Phase 3 Clinical Study

    U.S./Canada Phase 3 Clinical Study ARDS Patients Hospitalized with Covid-19 Infection Status Recruiting Primary Endpoint 28-Day Mortality Key Secondary Endpoints Ventilation Free Days 60-Day Mortality Target Population Adult subjects on invasive mechanical ventilation, both with and without addition

  18. Slide 18: EB07: Paridiprubart for Pulmonary Fibrosis

    EB07 Paridiprubart for Pulmonary Fibrosis

  19. Slide 19: Interstitial Lung Disease (ILD) and Fibrosis

    Interstitial Lung Disease (ILD) and Fibrosis ILD and Lung Fibrosis from Various Causes Culminate in a Pathway that is Meditated by TLR4 Activation Systemic Sclerosis- Activation of TLR4 and Fibrogenesis Idiopathic Pulmonary Associated Interstitial Fibrosis (IPF) Lung Disease (SSc-ILD) Interstitial l

  20. Slide 20: ILD and IPF – Treatment Paradigm

    ILD and IPF – Treatment Paradigm Current Management Relies on Treatments that Slow Progression But Do Not Resolve/Reverse Fibrosis Pharmacological Tx Monitoring Antifibrotics (nintedanib and pirfenidone) Symptoms Diagnosis Based on IPF Non-Pharmacological Tx Pulmonary function Long-term oxygen thera

  21. Slide 21: IPF and Systemic Sclerosis Burden and Market Size

    IPF and Systemic Sclerosis Burden and Market Size A Significant Healthcare Burden and a Growing Market Opportunity Global Systemic Sclerosis Market 7.6 $4.50B $4.00B IPF prevalence per 100,000 (USA & EU) $3.50B $3.00B 6% $2.50B CAGR $3.12B $2.00B $1.50B 44.3 Systemic Sclerosis prevalence of 7.2 - 44

  22. Slide 22: TLR4’s Therapeutic Potential in Fibrotic Diseases

    TLR4’s Therapeutic Potential in Fibrotic Diseases Summary of Preclinical Evidence TLR4 knock-out animal models display 1 attenuated fibrosis TLR4 antagonists lead to reduced fibrosis in 2 animal models TLR4 antagonists can reverse fibrosis in animal 3 models TLR4 agonists are predictors of disease 4

  23. Slide 23: Leveraging Existing Work from the ARDS Program (EB05)

    Leveraging Existing Work from the ARDS Program (EB05) Same Antibody as EB05 with a Significant Amount of Previous Preclinical, Clinical and Manufacturing Work Biological Activity in Favorable Safety Efficacy and Safety Manufacturing by Humans Established Profile Experience Leading Global CDMO Inhibi

  24. Slide 24: Proposed U.S. Phase 2 Clinical Study

    Proposed U.S. Phase 2 Clinical Study Patients with Idiopathic Pulmonary Fibrosis and in Participants With S.Sc. Interstitial Lung Disease Status IND being prepared – 15mg/kg/4 weeks Anticipated Duration 24 Months - Enrollment & Data Primary Endpoint Absolute Change From Baseline in Forced Vital Capa

  25. Slide 25: EB06 - Vitiligo

    EB06 - Vitiligo First-in-Class Anti-CXCL10 mAb

  26. Slide 26: Vitiligo

    Vitiligo CXCL10/CXCR3 Play a Key Role in the Pathogenesis of Vitiligo A Life-Altering Autoimmune Disease Langerhans Cells High Prevalence – 1% Global Population 50% Onset Before Age 20; Must be Managed for Decades Macules of Depigmentation Grow & Coalesce into Patches Associated with Type 1 Diabetes

  27. Slide 27: EB06 – Targeting the Chemokine CXCL10

    EB06 – Targeting the Chemokine CXCL10 Monoclonal Antibody that Directly Binds CXCL10 with High Affinity and Blocks it from Binding to CXCR3 EB06 – CXCL10 CXCR3A CXCR3B Drug Profile A humanized IgG1k monoclonal antibody Binds specifically to CXCL10 with high affinity Sequesters and renders CXCL10 ina

  28. Slide 28: Targeting the IFNγ-CXCL10-CXCR3 Chemokine Axis

    Targeting the IFNγ-CXCL10-CXCR3 Chemokine Axis EB06 is an anti-CXCL10 Monoclonal Antibody that Can Act on Different Stages of Vitiligo Vitiligo Innate (Non-lesional) Adaptive (Lesional) Apoptosis T-cell induced necrosis EB06 Inhibits: 3 2 1 Epidermal positioning of immune cells 1 CXCL10 CXCL10/CXC3B

  29. Slide 29: Vitiligo Treatment Paradigm

    Vitiligo Treatment Paradigm Limited Options with Topical Ruxolitinib as the Only Approved Product TREATMENT Topicals Significant Unmet Need Corticosteroids Calcineurin inhibitors Large unaddressed market due to lack of Ruxolitinib approved and effective options Only one approved drug with safety con

  30. Slide 30: A Significant Unaddressed Market

    A Significant Unaddressed Market Latent Market Comprised of Patients Waiting for Better Treatment Options Large Untapped Opportunity Large population but low proportion of patients seeking treatment due to lack of effective and safe treatments Diagnosed with 1.9M Vitiligo New therapies likely to dri

  31. Slide 31: Summary - CXCL10 Therapeutic Potential

    Summary - CXCL10 Therapeutic Potential Therapeutically Targeting Substantiated in Preclinical Studies EB06 – CXCL10 1 Melanocyte Apoptosis CXCL10/CXC3B mediates melanocyte apoptosis CXCR3A CXCR3B and activates anti-melanocytic CD8+ T-cells via CXCR3A 2 Knockout Mice CXCL10 -/- mice do not develop Vi

  32. Slide 32: Evidence Supporting EB06’s Biological Activity in Humans

    Evidence Supporting EB06’s Biological Activity in Humans Treatment with EB06 Traps CXCL10 in the Circulatory System and Renders it Biologically Inactive EB06 traps CXCL10 in circulation EB06 induces an increase in serum CXCL10 levels while rendering them biologically inactive CXCL10 (25nM) EB06 conc

  33. Slide 33: Phase 2 Proof of Concept

    Phase 2 Proof of Concept Moderate to Severe Non-Segmental (Generalized) Vitiligo Status CTA approved & IND being prepared Subjects Total of 102 evaluable patients randomized 1:1 (EB06 and Placebo) across up to 25 study centers in Canada Treatment Period EB06 (20 mg/kg) or placebo will be administere

  34. Slide 34: EB06: Anti-CXCL10 Monoclonal Antibody

    EB06: Anti-CXCL10 Monoclonal Antibody Summary and Next Steps Targeted Mechanism of Action 65 Subjects dosed Biological Activity Phase 2 Ready Manufacturing Binds free and bound CXCL10 No Significant AEs Demonstrated CTA Approved Leading CDMO NEXT STEPS Readying IND for submission to FDA CRO identifi

  35. Slide 35: Recent Transactions in Vitiligo Space

    Recent Transactions in Vitiligo Space Incyte Announces Agreement To Acquire Medicxi-Backed Villaris Therapeutics And Auremolimab (VM6), An Anti-IL-15Rβ Monoclonal Antibody - Stage of Development: Pre-clinical Asset - Monoclonal Antibody $70 million, with potential for up to $1.36 billion in addition

  36. Slide 36: Daniluromer

    Daniluromer First-in-Class sPLA2 Inhibitor Lead Indication: ACD Status: Topline Results Available

  37. Slide 37: Daniluromer (EB01): Treating Chronic Inflammation

    Daniluromer (EB01): Treating Chronic Inflammation Without the Safety Concerns of Current Therapies Inhibiting the Inflammation Cascade • sPLA2 inhibitors are designed to inhibit the inflammatory process at its inception • Exerts its anti-inflammatory activity upstream of currently approved NSAIDs •

  38. Slide 38: Allergic Contact Dermatitis (ACD)

    Allergic Contact Dermatitis (ACD) The Leading Occupational Health Issue Related to Dermatology ACD Represents a Significant Unmet Need 3,000+ 70% 0 Contact Unable to fully No Known ACD is a Type IV Hypersensitivity Reaction Allergens avoid allergen Labelled Drugs Immune system sensitized following i

  39. Slide 39: Significant Number of Patients with Chronic ACD

    Significant Number of Patients with Chronic ACD $4.7B Total Addressable Market Opportunity 7 major markets (US, UK, Germany, France, Spain, Italy, Japan) and Canada1 “ Physicians strongly desire additional treatment options, especially for hands and face2 “ACD…can make you quit your job.” 30M Patien

  40. Slide 40: EB01 Market Positioning

    EB01 Market Positioning Edesa’s Cream Addresses a Significant Unmet Need that Exists for Chronic ACD Patients Corticosteroids TCIs EB01 Viable for acute ACD patients Topical EB01 Cream Viable for chronic ACD patients Safe for long term use Positioned to be a leading therapy option for No boxed warni

  41. Slide 41: Confirmatory Phase 2B Design

    Confirmatory Phase 2B Design Protocol 210 total subjects Moderate-to-severe chronic ACD Double blind, placebo-controlled protocol 28-day treatment with topical EB01 cream Dose-Ranging EB01 Cream 0.2% Determine the Lowest Efficacious Dose EB01 Cream 1.0% EB01 Cream 2.0% Multiple endpoints designed fo

  42. Slide 42: Phase 2B Results - Composite CDSI and ISGA Scores

    Phase 2B Results - – Composite CDSI and ISGA Scores 1.0% EB01 Met Primary Endpoint and a Key Secondary Endpoint with Statistical Significance Total CDSI Score* Total ISGA Score* Summary of Results Mean % Improvement from Baseline % Patients with a ≥2 Point Improvement from Baseline P Value = 0.027 P

  43. Slide 43: Proposed Global Phase 3 Moderate to Severe Chronic ACD

    Proposed Global Phase 3 Moderate to Severe Chronic ACD Two Replicate Pivotal Phase Studies Will Likely Be Required* Protocol ~500 total subjects Moderate-to-severe chronic ACD Double blind, placebo-controlled protocol 28-day treatment with topical EB01 cream Dose EB01 Cream 1.0% Primary Endpoint ISG

  44. Slide 44: Experienced Leadership Team

    Experienced Leadership Team Pharmaceutical Pipelines, Corporate Development & Strategic Transactions Executive Management Team Par Nijhawan, MD, FRCPC, AGAF Michael Brooks, PhD Stephen Lemieux, CPA CEO and Board Director President Chief Financial Officer Gary Koppenjan Blair Gordon, PhD VP, Corporat

  45. Slide 45: Clinical Summary

    Clinical Summary First-in-Class Therapeutics for Immuno-Inflammatory Diseases EB05 (paridiprubart) Validated Phase 3 Program with Govt Funding EB01 (daniluromer) Phase 3 Ready w/ Partnering in Process EB06 – Vitiligo – Phase 2 Ready Significant Transactions in this Therapeutic Area and Pathway EB07

  46. Slide 46: www.EdesaBiotech.com

    www.EdesaBiotech.com [email protected]

Edesa Biotech — Investor Presentation (January 2024) on 6ix